Peravali, Monica
Wang, Haijun
Kim, Chul
Veytsman, Irina
Article History
Accepted: 7 September 2020
First Online: 18 September 2020
Compliance with Ethical Standards
:
: Monica Peravali, Haijun Wang, and Irina Veytsman declare no conflict of interest. Chul Kim has received research funding (paid to his institution) from AstraZeneca, Bristol-Myers Squibb, Novartis, Regeneron, Tesaro, Karyopharm, and Debiopharm, and has received compensation from Novartis for service as a consultant.
: This article does not contain any studies with human or animal subjects performed by any of the authors.